6,678 trials
Rheumatoid Arthritis
Primary: Proportion of Subjects Achieving a Clinical Disease Activity Index (CDAI) Decrease of Greater Than or Equal to 10 Points in the Cimzia Treatment Group Compared to the…
Acne Prone Skin
Primary: Cutaneous Tolerability Based on Visual Inspection - Erythema — 29; 33; 30; 29 participants
Swelling
Primary: Effect of Perioperative Steroid for the Postoperative Swelling After Orthognathic Surgery — 167.06; 190.73; 61.39; 57.62 ml — p=>0.05
The Duration of Motor Block May Vary Between 12-36 Hrs
Primary: Duration of Motor and Sensory Block of the Sciatic With 0.5% Bupivacaine and Ropivacaine After Ultrasound-guided Nerve-stimulator-Assisted Needle Positioning Beneath the…
Gonorrhoea
Primary: Microbiological Efficacy of Gentamicin and Azithromycin for the Treatment of Uncomplicated Gonococcal Infection — 100 percentage of participants — p=<0.05
Rheumatoid Arthritis
Primary: Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24 — 4.11; 3.75 scores on a scale
Open Abdomen
Primary: Primary Closure Rate — 75; 67 % of participants
Intracranial Aneurysms
Primary: Target Aneurysm Recurrence (TAR) Defined as Clinically Relevant Recurrence Resulting in Target Aneurysm Reintervention, Rupture/Re-rupture and/or Death From an Unknown…
Pain
Primary: Classification of Pain During Labor by Visual Analogue Scale — 57.0; 72.1 mm — p=0.01
Pain
Primary: Participant Pain Experience After Administration of Local Anesthesia to Numb the Gums and Teeth During Dental Treatment — 43; 33.1; 7.3; 9.8 units on a scale — p=0.23
Ischemic Heart Disease
Primary: To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary…
Relapsing Remitting Multiple Sclerosis
Primary: Difference Serum Levels of High-sensitive C-reactive Protein (Hs-CRP), Before and After of Supplementation — 1.2; -0.6 mg/L — p=<0.01
Major Depressive Disorder
Primary: Patients With Any Treatment Emergent Adverse Events (TEAEs) — 89 participants
Type 2 Diabetes · Inpatient Hyperglycemia
Primary: Mean Blood Glucose Concentration — 145; 172 mg/dl
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001